Friday, 22 May 2015
Topics
Meeting category
Date(s)
22 May 2015 - 23 May 2015
Location
Xi'an,
China
Organizer
Platinum Level Support
Sponsor logos
Asian Conference on Hepatitis and AIDS (ACHA) 2015
Related Enduring Materials
Enduring Materials
-
Opening Words
Polin Chan, MD
World Health Organization, China
Session 1: HIV -
The Advance and Challenge about cART in China
Treatment Failure and PI Monotherapy
Longterm Complications of HIV Treatment
Opportunities and Challenges of HIV Vaccine Research
HIV Functional Cure
Xiaoping Tang, MD, PhD
Guangzhou 8th People's Hospital, China
AbbVie-supported Symposium: 2nd line HIV ART in Resource Limited Settings -
Chair
Second-line ART in Resource Limited Settings
Free ARV Therapy in Yunnan Province
Huiqin Li
Yunan AIDS Caring Center, China
Session 2: HBV -
Stephen Locarnini, BSc(Hons), PhD, MBBS, FRC(Path)
Current Treatment Options for Hepatitis B
New HBV Treatment Options on the Horizon
HBV Infection in Special Populations and Its Control Strategy
How to Achieve Cure in HBV: A Virological Perspective
Victorian Infectious Diseases Reference Laboratory
New Biomarkers for Chronic Hepatitis B
Saturday, 23 May 2015
Session 3: HCV -
Hepatitis C Virus Infection Epidemiology and Management： Challenges We Are Facing in China
Xiaochun Wang, MSc, DrPH
Chinese CDC, China
Viral and Cellular Factors Important for Hepatitis C Virus Infection and Replication in Vitro and in Vivo
Current Treatment Challenges of Hepatitis C
Session 4: Hepatitis Co-infection -
Transmission Bottleneck of HIV-1 and HCV in Chinese Injected Drug Users
Fan Li, MD
China CDC, China
Treatment in Special Clinical Populations
AbbVie-supported Symposium: Current Advances in the Treatment of Chronic Hepatitis C - Does Hard to Treat Exist Anymore?
David Iser, PhD, FRACP
IsNorth West Specialist Centre, Australia
Session 5: Future Challenges -
Stephen Locarnini, BSc(Hons), PhD, MBBS, FRC(Path)
National Free Antiretroviral Therapy and Outcomes in China
Challenges in HCV: Policy and Advocacy
Victorian Infectious Diseases Reference Laboratory
Challenges in Viral Hepatitis: Community Perspectives
Global and Regional Hepatitis Action Plan – Future Opportunity and Consideration in China
Overview
Welcome
Dear Colleague,
We are pleased to look back on a very successful fourth edition of the Asian Conference on Hepatitis & AIDS, held in Xi'an, China from 22 - 23 May 2015.
The Organizing Committee and the organizing secretariat would like to thank the invited speakers and all participants for their contribution to this meeting! In particular we would like to thank our workshop sponsors: AbbVie and Gilead. Without their financial contribution this workshop would not have been made possible.
Yours sincerely,
The Organizing Committee
General Information
Unique Features
- A program with a special focus on the needs in China and Asia
- A true scientific platform for local and regional clinicians and clinical researchers to present their data
- A unique opportunity for regional clinicians, researchers, and pharmaceutical companies to meet and collaborate
- A true scientific platform for local and regional clinicians and clinical researchers to present their data
- A unique opportunity for regional clinicians, researchers, and pharmaceutical companies to meet and collaborate
Meeting Objectives
This meeting aims to:
- Provide education on the latest treatment options for HBV, HCV, HIV and associated co-infections
- Present the latest research data, especially in the Asian context and translate knowledge into clinical practice
- Provide a platform for interaction and dialogue among different disciplines and facilitate collaborations among local, national and regional communities
- Provide education on the latest treatment options for HBV, HCV, HIV and associated co-infections
- Present the latest research data, especially in the Asian context and translate knowledge into clinical practice
- Provide a platform for interaction and dialogue among different disciplines and facilitate collaborations among local, national and regional communities
Learning Objectives
After participating in this activity, participants will be able to:
- Summarize the most recent results in drug development (including most recent clinical trial results) for HBV, HCV, and HIV
- Integrate the latest scientific results into daily clinical care to improve the treatment quality for HBV, HCV and HIV-positive individuals
- Summarize the most recent results in drug development (including most recent clinical trial results) for HBV, HCV, and HIV
- Integrate the latest scientific results into daily clinical care to improve the treatment quality for HBV, HCV and HIV-positive individuals
Practical Information
Disclaimer
This workshop is intended for educational purposes only and aims to offer participants the opportunity to share information. The Organizing Secretariat of this workshop, Virology Education, cannot accept any liability for the scientific content of the sessions or for any claims which may result from the use of information or publications from this workshop. Virology Education disclaims all liability for injuries or losses of whatever nature incurred by individuals attending the workshop.
Liability and insurance
By registering for the conference participants agree that the organizers do not accept responsibility for medical-, travel- or personal insurance. Participants are advised to take out their own insurance policies.
Support
Platinum Level
Sliver Level
Endorsers
Language
Related Programs
